Pliant Therapeutics, Inc. (PLRX) announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial evaluating PLN-101095, an integrin v8 and v1 inhibitor, in combination with pembrolizumab, in patients with immune checkpoint inhibitor -refractory advanced or metastatic solid tumors. The company said interim results demonstrated PLN-101095 anti-tumor activity in combination with pembrolizumab, with three partial responses observed in cohort three at the 1000 mg administered orally twice daily dose, representing a 50% objective response rate at the highest dose tested to date. Also, PLN-101095 was generally well tolerated across all doses.
PLN-101095 is an oral small molecule inhibitor of integrins v8 and v1. It is currently being evaluated in an ongoing first-in human Phase 1 dose-escalation trial. The Phase 1 trial is currently enrolling the fourth of five potential cohorts.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.